lariam por tbl nob 8x250mg - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

lariam mefloquine 250mg tablets

pharmaco australia ltd - mefloquine hydrochloride, quantity: 274.09 mg (equivalent: mefloquine, qty 250 mg) - tablet, uncoated - excipient ingredients: ammonium alginate; crospovidone; lactose monohydrate; magnesium stearate; microcrystalline cellulose; purified talc; maize starch; poloxamer - malaria treatment: lariam is indicated for the treatment of acute attacks of malaria due to p.falciparum infection resistant to conventional antimalarial drugs. following therapy of mixed p.falciparum/p.vivax malaria with lariam relapse prophylaxis with an 8-aminoquinoline derivative (e.g. primaquine) should be considered in order to eliminate liver forms of p.vivax. malaria prophylaxis: for travellers to countries with documented chloroquine and antifolate combination ( [sulfadoxine/pyrimethamine] / [dapsone/pyrimethamine] ) resistant p.falciparum malaria, who are considered to be at high risk for malaria in view of their residence or travel (of up to 3 months duration) through rural areas (between the dusk to dawn period). for travellers hypersensitive to sulphonamides and sulphones, who are considered to be at high risk for malaria in view of their residence or travel (of up to 3 months duration) through rural areas, (between the dusk to dawn period) in countries with high level chloroquine-resistant p.fal

New Zealand - English - Medsafe (Medicines Safety Authority)

lariam

pharmaco (nz) ltd - mefloquine hydrochloride 274.09mg equivalent to mefloquine base 250mg - tablet - 250 mg - active: mefloquine hydrochloride 274.09mg equivalent to mefloquine base 250mg excipient: crospovidone ammonium calcium alginate lactose monohydrate magnesium stearate maize starch microcrystalline cellulose poloxamer purified talc - chemoprophylaxis, therapy and stand-by treatment of malaria. chemoprophylaxis chemoprophylaxis with lariam is recommended for travellers to malarious areas, particularly those travelling to areas where there is a high risk of infection with strains of p. falciparum resistant to other antimalarials. therapy lariam is indicated for the oral treatment of malaria, particularly when caused by strains of p. falciparum resistant to other antimalarials. it may also be used for the treatment of p. vivax and mixed malaria. stand-by treatment lariam is also prescribed as a stand-by medication, to be carried by the traveller and self-administered as an emergency measure for suspected malaria when prompt medical attention is unavailable within 24 hours.